Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Junshi Bio’s PARP Inhibitor Effective as Maintenance Therapy for Ovarian Cancer

publication date: Apr 13, 2023

Shanghai Junshi Biosciences reported its PARP inhibitor met its primary efficacy endpoint as a maintenance therapy in a Phase III trial for ovarian, fallopian tube or peritoneal cancer. The patients had previously experienced a full or partial response to platinum-based chemotherapy. Senaparib is being jointly developed by Junshi Biosciences and Impact Therapeutics. In 2020, the two companies formed a JV for China development of the candidate, with Junshi investing $43 million for a 50% stake in the JV while Impact contributed China rights to the drug. More details....

Stock Symbols: (HK: 1877; SHA: 688180)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital